Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy

Rony Kampalath; Karen Tran-Harding; Richard K G Do; Mishal Mendiratta-Lala; Vahid Yaghmai

doi:10.1016/j.mric.2021.05.013

Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy

Magn Reson Imaging Clin N Am. 2021 Aug;29(3):389-403. doi: 10.1016/j.mric.2021.05.013.

Authors

Rony Kampalath¹, Karen Tran-Harding¹, Richard K G Do², Mishal Mendiratta-Lala³, Vahid Yaghmai⁴

Affiliations

¹ Department of Radiological Sciences, University of California Irvine, 101 The City Drive South, Orange, CA 92868, USA.
² Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Radiology, Weill Medical College of Cornell University, New York, NY, USA. Electronic address: dok@mskcc.org.
³ Radiology, University of Michigan School of Medicine, 1500 East Medical Center Drive, UH B2A209R, Ann Arbor, MI 48109-5030, USA.
⁴ University of California, Irvine, 101 The City Drive South, Orange, CA 92868, USA.

PMID: 34243925
DOI: 10.1016/j.mric.2021.05.013

Abstract

Locoregional therapy (LRT) for hepatocellular carcinoma can be used alone or with other treatment modalities to reduce rates of progression, improve survival, or act as a bridge to cure. As the use of LRT expands, so too has the need for systems to evaluate treatment response, such as the World Health Organization and modified Response Evaluation Criteria In Solid Tumors systems and more recently, the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (TRA). Early validation results for LI-RADS TRA have been promising, and as research accrues, the TRA is expected to evolve in the near future.

Keywords: HCC; LI-RADS; Locoregional therapy; Response assessment; mRECIST.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / diagnostic imaging
Carcinoma, Hepatocellular* / therapy
Humans
Liver Neoplasms* / diagnostic imaging
Liver Neoplasms* / therapy
Magnetic Resonance Imaging
Retrospective Studies